Classic hallucinogens in the treatment of addictions
This review (2016) describes the historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, and other relevant research concerning hallucinogens, before suggesting directions for future research.
Authors
- Bogenschutz, M. P.
- Johnson, M. W.
Published
Abstract
Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions. In this paper we provide a comprehensive review of both historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, selectively review other relevant research concerning hallucinogens, and suggest directions for future research. Clinical trial data are very limited except for the use of LSD in the treatment of alcoholism, where a meta-analysis of controlled trials has demonstrated a consistent and clinically significant beneficial effect of high-dose LSD. Recent pilot studies of psilocybin-assisted treatment of nicotine and alcohol dependence had strikingly positive outcomes, but controlled trials will be necessary to evaluate the efficacy of these treatments. Although plausible biological mechanisms have been proposed, currently the strongest evidence is for the role of mystical or other meaningful experiences as mediators of therapeutic effects. Classic hallucinogens have an excellent record of safety in the context of clinical research. Given our limited understanding of the clinically relevant effects of classic hallucinogens, there is a wealth of opportunities for research that could contribute important new knowledge and potentially lead to valuable new treatments for addiction.
Research Summary of 'Classic hallucinogens in the treatment of addictions'
Study Details
- Study Typemeta
- Populationhumans
- Characteristicsliterature review
- Journal
Cited By (77)
Papers in Blossom that reference this study
Blainey, M. G., Brudner, R. M., Doyle, Z. et al. · Psychedelic Medicine (2025)
Bola, M., Brzezicka, A., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)
Tacla, C., Tap. S. C. · Addiction Biology (2024)
Bola, M., Hobot, J., Orłowski, P. et al. · Psychophysiology (2024)
Abate, A., Ali, S., Bawks, J. et al. · Med (2024)
Borkel, L. F., Del Pino, A. S., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Gross, R., Lev-Ran, S., Rabinowitz, J. · Frontiers in Psychiatry (2023)
Davis, A. K., Lancelotta, R., Ortiz Bernal, A. M. et al. · Frontiers in Psychiatry (2022)
Show all 77 papersShow fewer
Campbell, I., Dyck, J., Narine, K. et al. · Neuropharmacology (2022)
Dourron, H. M., Hendricks, P. S., Strauss, C. · Pharmacological Reviews (2022)
Dürsteler, K. M., Frölich, K., Köck, P. et al. · Journal of Substance Abuse Treatment (2022)
Jones, G. M., Lipson, J., Nock, M. K. · Scientific Reports (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Jones, G. M., Lipson, J., Nock, M. K. et al. · Scientific Reports (2022)
Baker-Jones, M., Carhart-Harris, R. L., Erritzoe, D. et al. · Frontiers in Pharmacology (2022)
Jones, G. M., Nock, M. K. · Scientific Reports (2022)
Argento, E., Choi, J., Christie, D. et al. · International Journal of Drug Policy (2022)
Jones, G. M., Nock, M. K. · Journal of Psychopharmacology (2022)
Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)
Baker, J. J., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)
Anjos-Santos, A., Barbosa, P., Barros-Santos, T. et al. · Frontiers in Pharmacology (2021)
Chiu, Y-T., Means, C. R., Nadkarni, V. et al. · Scientific Reports (2021)
Bogenschutz, M. P., Duane, J. H., Malone, T. C. et al. · Spirituality in Clinical Practice (2021)
Bouso, J. C., Galvão-Coelho, N. L., Opaleye, E. S. et al. · Drug and Alcohol Review (2021)
Ballentine, G., Bzdok, D., Friedman, S. F. · Science Advances (2021)
Dolder, P. C., Holze, F., Liechti, M. E. et al. · Scientific Reports (2021)
García, S., Loewinger, G., Loizaga-Velder, A. et al. · Frontiers in Pharmacology (2021)
Berlowitz, I., O’Shaughnessy, D. M., Quirk, F. et al. · Therapeutic Advances in Psychopharmacology (2021)
de Manicor, M., Galvão-Coelho, N. L., Gonzales, M. et al. · Psychopharmacology (2021)
Carbonaro, T. M., Gatch, M. B., Hoch, A. · ACS Pharmacology and Translational Science (2020)
Gómez-Busto, F. J., Ortiz, M. I. · Clinical Neuropsychiatry (2020)
Anderson, E. I., Brown, B. M., Cameron, L. P. et al. · Nature (2020)
Carhart-Harris, R. L., Forstmann, M., Gandy, S. et al. · Health Psychology Open (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Forbes, D., Gibson, K., Varker, T. et al. · Journal of Psychoactive Drugs (2020)
Amoroso, T., Averill, L. A., Barsuglia, J. P. et al. · Chronic Stress (2020)
Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)
Benko, J., Vranková, S. · Molecules (2020)
Davis, A. K., Erowid, E., Erowid, F. et al. · Frontiers in Psychiatry (2020)
Elices, M., Farré, M., Fonseca, F. et al. · Frontiers in Psychiatry (2020)
Forstmann, M., Heller, S. M., Prosser, A. M. B. et al. · PNAS (2020)
Banks, M. L., Leggett, E., Moerke, M. J. et al. · Experimental and Clinical Psychopharmacology (2019)
Libânio Osório Marta, R. F. · Drug Metabolism Reviews (2019)
Garcia-Romeu, A., Richards, W. A. · International Review of Psychiatry (2018)
Carhart-Harris, R. L., Daws, R. E., Haijen, E. C. H. M. et al. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L., Demetriou, L., Nutt, D. J. et al. · Neuropharmacology (2018)
Carhart-Harris, R. L., Kaelen, M., Leech, R. et al. · Neuropharmacology (2018)
Barrett, F. S., Kaelen, M., Preller, K. H. · International Review of Psychiatry (2018)
Carhart-Harris, R. L., Cassol, H., Erritzoe, D. et al. · Frontiers in Psychology (2018)
Barsuglia, J. P., Davis, A. K., Polanco, M. et al. · Journal of Psychoactive Drugs (2018)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. et al. · Journal of Psychopharmacology (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Gasser, P., Gutwinski, S., Hermle, L. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Barsuglia, J. P., Calvey, T., Kelmendi, B. et al. · Progress in Brain Research (2018)
Atasoy, S., Carhart-Harris, R. L., Deco, G. et al. · Scientific Reports (2017)
Barsuglia, J. P., Davis, A. K., Lynch, M. et al. · Journal of Psychedelic Studies (2017)
Argento, E., Braschel, M., Shannon, K. et al. · BMJ Open (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Phelps, J. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Kaelen, M. · Imperial College London (2017)
Bryson, A., Carter, O., Kanaan, R. A. et al. · International Journal of Neuropsychopharmacology (2017)
Lawn, W., McAndrew, A., Morgan, C. J. A. et al. · Current Opinion in Behavioral Sciences (2017)
Betz, R. M., Che, T., Dror, R. O. et al. · Cell (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Cabral, J., Canal, C. E., Murnane, K. S. · Journal of Psychopharmacology (2016)
Bates, L. W., Hendricks, P. S., Sweat, N. W. · Journal of Psychoactive Drugs (2016)
de Araujo, D. B., Tófoli, L.F. · International Review of Neurobiology (2016)
Balthazar, F. M., Bouso, J. C., Dos Santos, R. G. et al. · Journal of Psychopharmacology (2016)
Hendricks, P. S., Kosson, D. S., Lucas, P. et al. · Journal of Psychopharmacology (2016)
Barnwal, P., Das, S., Mondal, S. et al. · Therapeutic Advances in Psychopharmacology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Johnson, M. W., Tupper, K. W., Wood, E. et al. · Canadian Medical Association Journal (2015)